Universal Multi Traders

Universal Multi Traders is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on July 1, 2017, the company is registered as a micro enterprise under the MSME classification for the financial year 2024-25. Its registered office is located in Nagercoil, Tamil Nadu, India.

The company's export activities are primarily focused on two therapeutic categories: Antimalarial & Antiparasitic (55.1%) and Brand Names & OTC Products (44.9%). The top five products exported include Primaquine ($41K, Rank #5, 2.4% market share) and Volini ($33K, Rank #5, 1.1% market share). Notably, the portfolio concentration is high, with the top five products accounting for 100% of the export value.

Universal Multi Traders operates manufacturing facilities in Nagercoil, Tamil Nadu, India. The facilities are equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and specializations are not publicly disclosed.

The company's leadership includes:

• Mr. Mohammad Shafique: Director and Person of Significant Control (PSC).

Additional information regarding other key executives, such as the CEO, CFO, and other directors, is not publicly available.

Universal Multi Traders' export data indicates shipments to various countries, including the Maldives. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly disclosed. The company's export activities are primarily focused on markets where regulatory requirements are less stringent.

The company's export data indicates shipments to the Maldives, suggesting a presence in emerging markets. However, specific details regarding penetration in Africa, Latin America, and Southeast Asia, as well as WHO prequalification status, are not publicly available.

Universal Multi Traders' export activities are concentrated on a limited number of products, with the top five products accounting for 100% of the export value. This high portfolio concentration indicates a focused geographic strategy, potentially reducing diversification and increasing concentration risk. The company's strategic direction appears to be centered on maintaining a niche presence in select markets.

Specific information regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history for Universal Multi Traders is not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no engagement with the US market.

There is no publicly available information regarding Universal Multi Traders' WHO prequalification status or EU GMP certificates. The company's export data does not indicate shipments to markets requiring such certifications, suggesting that the company may not hold these certifications.

Universal Multi Traders is registered with the Ministry of Micro, Small, and Medium Enterprises (MSME) as a micro enterprise for the financial year 2024-25. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available.

There is no publicly available information regarding Form 483 observations, warning letters, or import alerts associated with Universal Multi Traders. The company's export data does not indicate any regulatory actions or compliance issues.

Universal Multi Traders operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. The company's export data indicates shipments of products such as Ropark 1mg, Syndopa Plus, Urimax 0.4mg, Tricort 40mg, and Aldactone 25mg to the Maldives. Specific information regarding top competitors in overlapping categories, market share comparisons, and head-to-head analyses is not publicly available.

Universal Multi Traders' key differentiators include a focused product portfolio with a high concentration on a limited number of products, indicating specialization in specific therapeutic areas. The company's export data suggests a niche presence in select markets, potentially allowing for tailored strategies and customer relationships.

Universal Multi Traders' current strategic direction appears to be centered on maintaining a niche presence in select markets, focusing on a limited number of products. The company's export data indicates shipments to markets where regulatory requirements are less stringent, suggesting a strategy that leverages existing capabilities and market access. Future outlook details are not publicly available.

Universal Multi Traders has a track record of exporting pharmaceutical products, with a total export value of $74K USD across 44 shipments. The company's export data indicates shipments of products such as Ropark 1mg, Syndopa Plus, Urimax 0.4mg, Tricort 40mg, and Aldactone 25mg to the Maldives. Specific information regarding export volume consistency and reliability indicators is not publicly available.

Importers should verify the following certifications when considering Universal Multi Traders as a supplier:

• WHO-GMP Certification: To ensure compliance with World Health Organization Good Manufacturing Practices.

• EU GMP Certification: To confirm adherence to European Union Good Manufacturing Practices.

• ISO Certification: To assess the company's quality management systems.

Verification can be conducted by requesting copies of the certificates directly from the company and cross-referencing them with the issuing authorities' databases.

When conducting due diligence on Universal Multi Traders, consider the following steps:

• Verify Certifications: Request copies of WHO-GMP, EU GMP, and ISO certifications and validate them with the issuing authorities.

• Assess Regulatory Compliance: Confirm the company's compliance with CDSCO and state drug controller regulations.

• Evaluate Export History: Review the company's export data for consistency and reliability.

• Check for Regulatory Actions: Investigate any past Form 483 observations, warning letters, or import alerts.

• Review Financial Stability: Analyze the company's financial statements for signs of stability and growth.

Red flags to watch for include expired or unverifiable certifications, a history of regulatory non-compliance, and inconsistent export records. Recommended pre-order checks involve verifying product quality through samples and assessing the company's ability to meet delivery timelines.